160 related articles for article (PubMed ID: 26504067)
1. Long-term Survival with Ipilimumab: Experience from a National Expanded Access Program for Patients with Melanoma.
Krajsová I; Arenberger P; Lakomý R; Kubala E; Březinová I; Poprach A; Šťastný M; Mužík J; Melichar B
Anticancer Res; 2015 Nov; 35(11):6303-10. PubMed ID: 26504067
[TBL] [Abstract][Full Text] [Related]
2. Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy).
Di Giacomo AM; Danielli R; Calabrò L; Bertocci E; Nannicini C; Giannarelli D; Balestrazzi A; Vigni F; Riversi V; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2011 Apr; 60(4):467-77. PubMed ID: 21170646
[TBL] [Abstract][Full Text] [Related]
3. Single-center experience with ipilimumab in an expanded access program for patients with pretreated advanced melanoma.
Wilgenhof S; Du Four S; Vandenbroucke F; Everaert H; Salmon I; Liénard D; Marmol VD; Neyns B
J Immunother; 2013 Apr; 36(3):215-22. PubMed ID: 23502769
[TBL] [Abstract][Full Text] [Related]
4. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
5. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme.
Di Giacomo AM; Calabrò L; Danielli R; Fonsatti E; Bertocci E; Pesce I; Fazio C; Cutaia O; Giannarelli D; Miracco C; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2013 Jun; 62(6):1021-8. PubMed ID: 23591982
[TBL] [Abstract][Full Text] [Related]
6. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
Weber J; Gibney G; Kudchadkar R; Yu B; Cheng P; Martinez AJ; Kroeger J; Richards A; McCormick L; Moberg V; Cronin H; Zhao X; Schell M; Chen YA
Cancer Immunol Res; 2016 Apr; 4(4):345-53. PubMed ID: 26873574
[TBL] [Abstract][Full Text] [Related]
7. Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.
Kelderman S; Heemskerk B; van Tinteren H; van den Brom RR; Hospers GA; van den Eertwegh AJ; Kapiteijn EW; de Groot JW; Soetekouw P; Jansen RL; Fiets E; Furness AJ; Renn A; Krzystanek M; Szallasi Z; Lorigan P; Gore ME; Schumacher TN; Haanen JB; Larkin JM; Blank CU
Cancer Immunol Immunother; 2014 May; 63(5):449-58. PubMed ID: 24609989
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and tolerability of ipilimumab: experiences from 198 patients included in a named-patient program in various daily-practice settings and multiple institutions.
Eigentler TK; Schlaak M; Hassel JC; Loquai C; Stoffels I; Gutzmer R; Pätzold S; Mohr P; Keller U; Starz H; Ulrich J; Tsianakas A; Kähler K; Hauschild A; Janssen E; Schuler-Thurner B; Weide B; Garbe C
J Immunother; 2014 Sep; 37(7):374-81. PubMed ID: 25075567
[TBL] [Abstract][Full Text] [Related]
9. Open-label, multicenter, single-arm phase II DeCOG-study of ipilimumab in pretreated patients with different subtypes of metastatic melanoma.
Zimmer L; Eigentler TK; Kiecker F; Simon J; Utikal J; Mohr P; Berking C; Kämpgen E; Dippel E; Stadler R; Hauschild A; Fluck M; Terheyden P; Rompel R; Loquai C; Assi Z; Garbe C; Schadendorf D
J Transl Med; 2015 Nov; 13():351. PubMed ID: 26541511
[TBL] [Abstract][Full Text] [Related]
10. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma.
Diem S; Kasenda B; Spain L; Martin-Liberal J; Marconcini R; Gore M; Larkin J
Br J Cancer; 2016 Feb; 114(3):256-61. PubMed ID: 26794281
[TBL] [Abstract][Full Text] [Related]
11. Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumab.
Valpione S; Martinoli C; Fava P; Mocellin S; Campana LG; Quaglino P; Ferrucci PF; Pigozzo J; Astrua C; Testori A; Chiarion-Sileni V
Eur J Cancer; 2015 Sep; 51(14):2086-94. PubMed ID: 26227432
[TBL] [Abstract][Full Text] [Related]
12. Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy.
Danielli R; Ridolfi R; Chiarion-Sileni V; Queirolo P; Testori A; Plummer R; Boitano M; Calabrò L; Rossi CD; Giacomo AM; Ferrucci PF; Ridolfi L; Altomonte M; Miracco C; Balestrazzi A; Maio M
Cancer Immunol Immunother; 2012 Jan; 61(1):41-8. PubMed ID: 21833591
[TBL] [Abstract][Full Text] [Related]
13. Ipilimumab in treatment-naive and previously treated patients with metastatic melanoma: retrospective analysis of efficacy and safety data from a phase II trial.
Thompson JA; Hamid O; Minor D; Amin A; Ron IG; Ridolfi R; Assi H; Berman D; Siegel J; Weber JS
J Immunother; 2012 Jan; 35(1):73-7. PubMed ID: 22130164
[TBL] [Abstract][Full Text] [Related]
14. Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated with Ipilimumab.
Koguchi Y; Hoen HM; Bambina SA; Rynning MD; Fuerstenberg RK; Curti BD; Urba WJ; Milburn C; Bahjat FR; Korman AJ; Bahjat KS
Cancer Res; 2015 Dec; 75(23):5084-92. PubMed ID: 26627641
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme.
Chiarion Sileni V; Pigozzo J; Ascierto PA; Grimaldi AM; Maio M; Di Guardo L; Marchetti P; de Rosa F; Nuzzo C; Testori A; Cocorocchio E; Bernengo MG; Guida M; Marconcini R; Merelli B; Parmiani G; Rinaldi G; Aglietta M; Grosso M; Queirolo P
J Exp Clin Cancer Res; 2014 Apr; 33(1):30. PubMed ID: 24708900
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.
Maio M; Danielli R; Chiarion-Sileni V; Pigozzo J; Parmiani G; Ridolfi R; De Rosa F; Del Vecchio M; Di Guardo L; Queirolo P; Picasso V; Marchetti P; De Galitiis F; Mandalà M; Guida M; Simeone E; Ascierto PA
Ann Oncol; 2013 Nov; 24(11):2911-5. PubMed ID: 24067719
[TBL] [Abstract][Full Text] [Related]
17. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Schadendorf D; Hodi FS; Robert C; Weber JS; Margolin K; Hamid O; Patt D; Chen TT; Berman DM; Wolchok JD
J Clin Oncol; 2015 Jun; 33(17):1889-94. PubMed ID: 25667295
[TBL] [Abstract][Full Text] [Related]
18. Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.
Zimmer L; Vaubel J; Mohr P; Hauschild A; Utikal J; Simon J; Garbe C; Herbst R; Enk A; Kämpgen E; Livingstone E; Bluhm L; Rompel R; Griewank KG; Fluck M; Schilling B; Schadendorf D
PLoS One; 2015; 10(3):e0118564. PubMed ID: 25761109
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.
Del Vecchio M; Di Guardo L; Ascierto PA; Grimaldi AM; Sileni VC; Pigozzo J; Ferraresi V; Nuzzo C; Rinaldi G; Testori A; Ferrucci PF; Marchetti P; De Galitiis F; Queirolo P; Tornari E; Marconcini R; Calabrò L; Maio M
Eur J Cancer; 2014 Jan; 50(1):121-7. PubMed ID: 24100024
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab versus Ipilimumab in Advanced Melanoma.
Robert C; Schachter J; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank CU; Hamid O; Mateus C; Shapira-Frommer R; Kosh M; Zhou H; Ibrahim N; Ebbinghaus S; Ribas A;
N Engl J Med; 2015 Jun; 372(26):2521-32. PubMed ID: 25891173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]